Sargramostim in patients with Crohn’s disease: results of a phase 1–2 study
- 8 April 2009
- journal article
- research article
- Published by Springer Nature in The Esophagus
- Vol. 44 (6) , 535-543
- https://doi.org/10.1007/s00535-009-0029-7
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Sargramostim for Active Crohn's DiseaseNew England Journal of Medicine, 2005
- An open‐labelled study of granulocyte colony‐stimulating factor in the treatment of active Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2005
- Identification of GM-CSF in Paneth cells using single-cell RT-PCRBiochemical and Biophysical Research Communications, 2003
- Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factorThe Lancet, 2002
- GM-CSF treatment for Crohn's disease: a stimulating new therapy?2002
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2002
- The epidemiology and natural history of Crohn’s disease in population‐based patient cohorts from North America: a systematic reviewAlimentary Pharmacology & Therapeutics, 2002
- Phase I and Pharmacokinetic Study of Weekly 5-Fluorouracil Administered with Granulocyte-Macrophage Colony-Stimulating Factor and High-Dose Leucovorin: A Potential Role for Growth Factor as Mucosal ProtectantCancer Investigation, 1999
- Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor.1998
- Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.1995